(Q35814369)

10 August 2017

1 reference

title

Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response (English)

1 reference

10 August 2017

Jeffrey R Bishop

1

1 reference

PubMed ID

15212583

10 August 2017

Vicki L Ellingrod

series ordinal

2

1 reference

PubMed ID

15212583

10 August 2017

language of work or name

1 reference

1 July 2004

1 reference

10 August 2017

15

1 reference

based on heuristic

inferred from page(s)

published in

Pharmacogenomics

1 reference

10 August 2017

5

1 reference

10 August 2017

463-477

1 reference

10 August 2017

5

1 reference

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Dextromethorphan O-demethylation polymorphism in an African-American population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Cytochrome P450 polymorphisms and response to antipsychotic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Allelic Variation of Human Serotonin Transporter Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Polymorphism in serotonin transporter gene associated with susceptibility to major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Serotonin transporter gene associated with lithium prophylaxis in mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association of the dopamine transporter gene (DAT1) with poor methylphenidate response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Chromosomal localization of the genes encoding two forms of the G protein beta polypeptide, beta 1 and beta 3, in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

SSRIs antidepressant activity is influenced by G beta 3 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Functional genomics approaches in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Cloning, heterologous expression, and chromosomal localization of human inositol polyphosphate 1-phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Catechol O -methyltransferase val 158 -met genotype and individual variation in the brain response to amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Donepezil therapy in clinical practice: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Metrifonate treatment of AD: influence of APOE genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

beta-Amyloid efflux mediated by p-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Systematic screening for mutations in the human serotonin-2A (5-HT 2A ) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.5.463

21 January 2018

Identifiers

DOI

10.1517/14622416.5.5.463

1 reference

10 August 2017

1 reference

PubMed ID

15212583